Pura Vida Investments LLC increased its holdings in Regenxbio Inc (NASDAQ:RGNX) by 17.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,920 shares of the biotechnology company’s stock after purchasing an additional 5,100 shares during the period. Pura Vida Investments LLC owned approximately 0.11% of Regenxbio worth $1,118,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Citigroup Inc. increased its holdings in shares of Regenxbio by 1,042.8% during the second quarter. Citigroup Inc. now owns 29,348 shares of the biotechnology company’s stock worth $580,000 after buying an additional 26,780 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Regenxbio by 222.7% during the second quarter. Goldman Sachs Group Inc. now owns 113,906 shares of the biotechnology company’s stock worth $2,250,000 after buying an additional 78,606 shares in the last quarter. TIAA CREF Investment Management LLC increased its holdings in shares of Regenxbio by 33.6% during the second quarter. TIAA CREF Investment Management LLC now owns 74,175 shares of the biotechnology company’s stock worth $1,465,000 after buying an additional 18,647 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Regenxbio by 32.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 97,695 shares of the biotechnology company’s stock worth $1,930,000 after buying an additional 23,971 shares in the last quarter. Finally, Redmile Group LLC increased its holdings in shares of Regenxbio by 35.4% during the second quarter. Redmile Group LLC now owns 1,718,671 shares of the biotechnology company’s stock worth $33,944,000 after buying an additional 449,540 shares in the last quarter. 68.73% of the stock is owned by institutional investors.

In other news, CFO Vittal Vasista sold 5,000 shares of the stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $27.39, for a total transaction of $136,950.00. Following the sale, the chief financial officer now directly owns 99,594 shares of the company’s stock, valued at $2,727,879.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Donald J. Hayden, Jr. sold 40,000 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $28.70, for a total transaction of $1,148,000.00. Following the sale, the director now directly owns 20,000 shares in the company, valued at $574,000. The disclosure for this sale can be found here. Insiders have sold 144,000 shares of company stock worth $4,415,296 over the last three months. 17.00% of the stock is owned by insiders.

Shares of Regenxbio Inc (NASDAQ:RGNX) opened at $28.15 on Thursday. Regenxbio Inc has a 52 week low of $16.30 and a 52 week high of $36.10.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.04. Regenxbio had a negative net margin of 764.06% and a negative return on equity of 39.33%. The business had revenue of $1.34 million for the quarter. equities research analysts forecast that Regenxbio Inc will post -2.71 earnings per share for the current year.

Several analysts have recently weighed in on RGNX shares. Chardan Capital raised their price objective on shares of Regenxbio from $75.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. Bank of America reaffirmed a “buy” rating and set a $38.00 price objective (up previously from $33.00) on shares of Regenxbio in a report on Monday, October 9th. BidaskClub raised shares of Regenxbio from a “hold” rating to a “buy” rating in a report on Thursday, December 7th. TheStreet lowered shares of Regenxbio from a “c” rating to a “d+” rating in a report on Tuesday, November 28th. Finally, Zacks Investment Research lowered shares of Regenxbio from a “buy” rating to a “hold” rating in a report on Friday, November 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $42.43.

WARNING: This article was originally published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/12/14/pura-vida-investments-llc-acquires-5100-shares-of-regenxbio-inc-rgnx.html.

About Regenxbio

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.